Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Hypertrophy Clear all
Completed No phase listed Observational

ARI103094-Follow-Up Study for REDUCE Study Subjects

NCT00883909
View directory record Official record
Conditions
Neoplasms, Prostate
Interventions
dutasteride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older · Male only
Enrollment
2,795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
73
States / cities
Anchorage, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

5-Alpha Reductase and Anabolic Effects of Testosterone

NCT00475501
View directory record Official record
Conditions
Male Hypogonadism, Muscle Atrophy, Sarcopenia, Benign Prostate Hypertrophy
Interventions
Testosterone Enanthate, Finasteride, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures

NCT02195622
View directory record Official record
Conditions
Benign Prostatic Hypertrophy Requiring Surgical Intervention
Interventions
Lumenis VersaCut Morcellator, Wolf Piranha Morcellator
Device
Lead sponsor
Indiana Kidney Stone Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Early Apical Release vs Classic Holmium Laser Enucleation of the Prostate: Randomized Controlled Trial Comparing Post-Operative Incontinence Rates and Surgical Outcomes

NCT04566588
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
EAR HoLEP, Classic HoLEP
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH

NCT04987892
View directory record Official record
Conditions
BPH
Interventions
UroLift System, Tamsulosin Hydrochloride
Device · Drug
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

NCT00634608
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions
Health Information Prescription
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Self-Administered Maneuver to Relieve Symptoms Suggestive of Benign Prostatic Hyperplasia

NCT01387893
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
the Digital Repetitive Infrapubic Pressure maneuver
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
45 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional

Saw Palmetto Extract in Benign Prostatic Hyperplasia

NCT00037154
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Saw Palmetto
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
2
States / cities
Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed Not applicable Interventional

Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams

NCT02167009
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Embosphere Microspheres
Device
Lead sponsor
Tampa General Hospital
Other
Eligibility
50 Years to 85 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

NCT04103450
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
45 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
31
States / cities
Huntsville, Alabama • Lincoln, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 11, 2026, 8:23 AM EDT
Not yet recruiting Phase 2 Interventional

RADA16 for Aquablation Day Case

NCT06948331
View directory record Official record
Conditions
Hematuria, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
PuraStat
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Urodynamic Feasibility Study Utilizing the UroLift® System

NCT04271020
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift
Device
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 11, 2026, 8:23 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Comparing UroLift Experience Against Rezūm

NCT04338776
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift, Rezum
Device
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
7
States / cities
Los Angeles, California • Royal Oak, Michigan • Garden City, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)

NCT02505919
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
AQUABEAM System, Transurethral Resection of the Prostate (TURP)
Device · Procedure
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • La Mesa, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 11, 2026, 8:23 AM EDT
Withdrawn Phase 4 Interventional

Role of Prophylactic Postoperative Antibiotics in HoLEP

NCT05274672
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Urinary Tract Infections
Interventions
Nitrofurantoin, Cephalexin, Sulfamethoxazole Trimethoprim Combination, Ciprofloxacin, Holmium Laser Enucleation of prostate
Drug · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT02326454
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
talaporfin sodium, Saline, Drug Activator 100 J/cm, Drug Activator 200 J/cm
Drug · Device
Lead sponsor
Light Sciences Oncology
Industry
Eligibility
40 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Anniston, Alabama • Huntsville, Alabama • Anchorage, Alaska + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

NCT01002222
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Interventions
MCS-2
Drug
Lead sponsor
Health Ever Bio-Tech Co., Ltd.
Industry
Eligibility
40 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects

NCT00710749
View directory record Official record
Conditions
Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
Interventions
Disposable device, Digital device, Clinic flow measurement
Device
Lead sponsor
Wellspect HealthCare
Industry
Eligibility
45 Years to 85 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer

NCT00706966
View directory record Official record
Conditions
Nonmalignant Neoplasm, Prostate Cancer
Interventions
dutasteride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed Not applicable Interventional

Safety and Effectiveness Study of the Zenflow Spring System

NCT04987138
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Interventions
Zenflow Spring System, Sham Procedure
Device
Lead sponsor
Zenflow, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Glenview, Illinois • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Deprescribing Tamsulosin in Older Men

NCT05415748
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Tamsulosin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 80 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)

NCT02637960
View directory record Official record
Conditions
Nocturia
Interventions
Fedovapagon 2 mg, Placebo
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
48
States / cities
Anniston, Alabama • Goodyear, Arizona • Lincoln, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

NCT01139762
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate
Interventions
Tadalafil, Placebo, Finasteride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Davis, California • Fresno, California • Laguna Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Sep 11, 2026, 8:23 AM EDT
Recruiting Not applicable Interventional

Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate

NCT06179654
View directory record Official record
Conditions
Benign Prostatic Hyperplasia With Outflow Obstruction, Urinary Retention, Lower Urinary Tract Symptoms
Interventions
Preoperative pelvic floor physical therapy
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 11, 2026, 8:23 AM EDT